RXFP4

Across TCGA pan-cancer cohorts, RXFP4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RXFP4 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RXFP4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RXFP4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LUSC, PRAD, and UCEC are the cancer types where RXFP4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.073	0.762	<.001	16	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.630	.039	2	view →
SKCM	OS	Median	II,III,IV	0.840	0.289	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RXFP4–LUSC (OS)

Open the LUSC breakdown →